Advanced Enzyme FY26 profit rises; ₹1.35 dividend

Key update and why it matters

Advanced Enzyme Technologies has reported its audited financial results for the year ended March 31, 2026 (FY26), alongside fourth quarter numbers. The company posted higher consolidated revenue from operations and higher net profit compared with the previous year. Along with the results, the board recommended a final dividend and took a set of corporate actions, including ESOP share allotment and director-related approvals. The disclosures matter for investors tracking earnings quality, payout decisions, and share count changes. The company also announced a scheduled conference call for analysts and investors, which typically helps markets assess management commentary and business drivers.

Board meeting outcome: results, dividend, and corporate actions

The Board of Directors met on May 09, 2026 and approved the audited annual financial results, both standalone and consolidated, for FY26, along with the fourth quarter results. The board recommended a final dividend of ₹1.35 per equity share for FY26, subject to shareholder approval at the company’s ensuing 37th Annual General Meeting. The company stated that this dividend represents 67.5% on the face value of ₹2 per share. The board also approved director reappointments as part of routine governance items. Separately, it approved the allotment of equity shares under the company’s ESOP Scheme 2022.

FY26 consolidated performance: revenue and profit improved

On a consolidated basis, Advanced Enzyme Technologies reported revenue from operations of ₹7,457.57 million in FY26. This compares with ₹6,369.10 million in the previous year, indicating a rise in the top line. Net profit for FY26 was reported at ₹1,736.08 million, up from ₹1,339.74 million a year earlier. The company also reported total comprehensive income of ₹2,684.19 million, compared with ₹1,527.96 million in the previous year. These metrics indicate a stronger year for profitability and overall income on a consolidated basis, based on the audited numbers approved by the board.

FY26 standalone performance: higher revenue and net profit

On a standalone basis, the company reported revenue from operations of ₹4,527.66 million for FY26. This is higher than ₹3,514.11 million in the previous year. Standalone net profit for FY26 stood at ₹1,318.06 million, up from ₹1,024.20 million previously. The standalone numbers are important because they reflect the core entity’s performance, separate from consolidation effects. For investors, the consolidated results capture the group performance, while the standalone results help assess the parent company’s financial position.

Dividend decision: final payout recommended, interim deferred

The board recommended a final dividend of ₹1.35 per equity share for FY26. The company clarified that the final dividend is subject to shareholder approval at the forthcoming AGM. In the same set of board outcomes, the company said it deferred declaring an interim dividend. The stated reason was to preserve capital flexibility while evaluating potential strategic avenues and corporate actions to maximise long-term shareholder value. This framing suggests the company wants room for decisions that may require cash deployment, although no specific corporate action was detailed in the provided disclosure.

ESOP share allotment and share capital changes

The board approved allotment of 49,350 equity shares of face value ₹2 per share under the Advanced Enzyme Technologies Limited Employees Stock Options Scheme 2022, pursuant to the exercise of options. Following this allotment, the paid-up share capital increased from ₹22,38,53,600 (11,19,26,800 equity shares of ₹2 each) to ₹22,39,52,300 (11,19,76,150 equity shares of ₹2 each). For shareholders, such allotments marginally increase the equity base and can have a small impact on per-share metrics, depending on the overall size of the issuance relative to the existing share count.

Audit opinion and regulatory disclosure trail

The statutory auditors, M S K A & Associates LLP, issued an unmodified audit opinion on both the standalone and consolidated financial results for FY26, as stated by the company. The company also referenced disclosure compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in connection with its investor communication. The conference call announcement was communicated to stock exchanges on May 05, 2026 by Company Secretary and Head of Legal, Sanjay Basantani.

Conference call: schedule and participation details

Advanced Enzyme Technologies announced a conference call for analysts and investors to discuss its financial results for the quarter and year ended March 31, 2026. The call is scheduled for Tuesday, May 12, 2026 at 09:00 hours IST. The company shared dial-in numbers (+91 86 3416 8438 / +91 86 4536 6489) and a participant PIN for international participants (4773312#). For investor queries or RSVP, the company listed its Investor Relations contact as Ronak Saraf (ir@advancedenzymes.com, +91 86578 64146). The company also stated that conference call information was uploaded on its official website.

Recent reported quarterly data points (for context)

Beyond the FY26 audited annual results, the provided data includes quarterly figures for comparison. For Q2 FY26, the company reported total income of ₹1,948.1 million, total expenses of ₹1,352.7 million, profit before tax of ₹595.4 million, tax of ₹148.1 million, and profit after tax of ₹447.4 million, along with EPS of ₹3.87. For the quarter ended December 2025, consolidated net sales were reported at ₹1,719.5 million (up 1.68% year-on-year), while standalone net sales were reported at ₹955.8 million (down 5.24% year-on-year). These quarterly data points, presented alongside the annual results disclosure set, help investors place the FY26 outcome within a more recent run-rate context.

Summary table: FY26 vs FY25 (audited annual)

Market impact and what investors may track next

The immediate market relevance of the announcement is anchored in the audited FY26 improvement in consolidated revenue and net profit, and the board’s decision on shareholder payout. The final dividend recommendation of ₹1.35 per share sets an expectation for the upcoming AGM process, while the decision to defer an interim dividend signals a preference for keeping capital available. Investors will also factor in the ESOP allotment and the updated paid-up share capital when analysing per-share performance and share count changes. The company’s scheduled May 12, 2026 conference call is a key near-term event because it may provide colour on business performance and any evaluation of strategic avenues referenced by the board.

Conclusion

Advanced Enzyme Technologies closed FY26 with higher consolidated and standalone revenue from operations and higher net profit compared with FY25, based on audited results approved on May 09, 2026. The board recommended a ₹1.35 final dividend per share, deferred an interim dividend, and approved an ESOP-related share allotment that increased paid-up share capital. The next formal milestone is the shareholder vote on the final dividend at the ensuing 37th AGM. In the near term, management engagement with investors is expected through the scheduled analyst and investor call on May 12, 2026 at 09:00 IST.